Hengrui Pharma Wins China Approval for Cholesterol-Lowering Drug Rivocibart

MT Newswires Live11-12

Jiangsu Hengrui Pharmaceuticals (HKG:1276) said China's National Medical Products Administration approved its rivocibart injection for treating homozygous familial hypercholesterolemia in adults and adolescents aged 12 and older.

Rivocibart's approval was based on a Phase III trial involving patients aged 12 and older with the rare inherited condition, according to a Thursday Hong Kong bourse filing.

Hengrui Pharma said its cumulative research and development investment in the drug was about 302.9 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment